Wedge Capital Management L L P NC Has $29.79 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Wedge Capital Management L L P NC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,775 shares of the biopharmaceutical company’s stock after purchasing an additional 8,063 shares during the period. Wedge Capital Management L L P NC’s holdings in Regeneron Pharmaceuticals were worth $29,790,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. WPG Advisers LLC boosted its stake in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $29,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ REGN opened at $797.00 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average of $665.31 and a 200-day moving average of $713.04. The firm has a market capitalization of $82.06 billion, a price-to-earnings ratio of 19.70, a PEG ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s business and pipeline prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Positive Sentiment: Recent analysis highlighted continued strength in Eylea HD and Dupixent, along with oncology growth and pipeline progress. The stock has risen 21.9% over the past month, although the sharp advance may also increase profit-taking risk. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio, but the figures also contain an undefined percentage change and appear unreliable. Consequently, the data provides no meaningful indication of short-covering or bearish positioning.
• Negative Sentiment: Several law firms, including Pomerantz, Gross, Faruqi & Faruqi, and Hagens Berman, are promoting or reminding investors about a securities class action against Regeneron. The litigation follows disclosures that a Phase 3 melanoma therapy trial failed, an event reportedly associated with an approximately $11 billion market-capitalization loss. The legal notices themselves do not establish wrongdoing, but they add reputational and potential financial-risk concerns. Investors covered by the proposed class period may face a September 14, 2026 lead-plaintiff deadline. REGN Investor Alert

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on REGN shares. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Finally, Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $797.75.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.